格列美脲与瑞格列奈治疗初发2型糖尿病的疗效对比

Curative effect of glimepiride and repaglinide on early stage type 2 diabetes

目的比较格列美脲和瑞格列奈治疗初发2型糖尿病的临床疗效。方法将60例初发2型糖尿病患者随机分为格列美脲组30例与瑞格列奈组30例,观察12周。治疗前后监测患者空腹血糖(FBG)、餐后2h血糖(2hPBG)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)、餐后2h胰岛素(2hPINS)、空腹C肽(FCP)、餐后2hC肽(2hPCP)及体质指数(BMI)。同时了解治疗期间低血糖发生情况。结果两组治疗后FBG、2hPBG及HbA1c均明显下降(P<0.05),但诺和龙组治疗后2hPBG较格列美脲组降低更明显,两组间比较差异有统计学意义(P<0.05);治疗后两组间FBG、HbA1c、FINS、FCP之间比较差异无统计学意义(P>0.05)。结论格列美脲和瑞格列奈用于治疗初发的2型糖尿病患者,能够保护胰岛β细胞功能,延缓糖尿病进程,疗效确切安全,均可以作为初发2型糖尿病患者的首选药物。

Objective To compare the clinical effect of glimepiride and repaglinide on the early stage of type 2 diabetes.Methods 60 cases of type 2 diabetes were randomly divided into 2 groups,and treated with glimepiride（n=30）or repaglinid（n=30） for 12 weeks.FBG、2hPBG、HbA1c、FINS、2hPINS、FCP、2hPCP BMI were measured before and after the treatment.The frequency of hypoglycemia event was observed for the duration.Results The levels of FBG,2hPBG HbA1c in both groups decreased obviously after 12-weeks treatment as compared with those at baseline（P0.05）.The treatment with repaglinide was more efficient than that with glimepiride in 2hPBG excursion in patients with type 2 diabetes（P0.05）.The comparision of FBG、HbA1c、FINS FCP between two groups was no significant difference（P0.05）.Conclusion The efficacy of glimepiride or repaglinide is significant,so both of them are the first choice for patients with type 2 diabetes on the early stage.